---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-000217"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:19.648739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%

## Summary
- Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.
- 12-month survival doubled: 44.4% vs 22.3%; 24-month survival fivefold: 12.9% vs 2.6%.
- Safety profile consistent; serious TEAE 56.1% vs 56.4%; death-related TEAE 12.3% vs 16.7%.
- Biomarker data suggest potential predictive value for KRAS, ARID1A; increased CD8+ and NK cells in combination arm.
- Seventeen patients remain alive in elraglusib arm (3 >24 mo); none on GnP alone as of Nov 2025.

## SEC filing metadata
- accession: 0001683168-26-000217
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/0001683168-26-000217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-000217
- JSON: https://secwatch.observer/filing/0001683168-26-000217.json
- Plain text: https://secwatch.observer/filing/0001683168-26-000217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.